The essence of the project is exchange of scientific experience and innovations in order to improve and accelerate the development and research of medicinal products at an early stage with a special focus on processes and technology.
The study placement of nine scientific experts from Farmak JSC at centers of European scientific institutions-participants of the Consortium is on the agenda of the first year of the project. Eight scientists from European universities will be trained at Farmak JSC laboratories from June 2018.
A total of 43 participants from Farmak JSC will take part in the ORBIS project.
This is the second project after the VAHVISTUS project at Farmak JSC, to be funded by the European Commission within the framework of the Horizon 2020 program.
“The best employees of scientific institutions and manufacturing companies will work together to improve the technological profile of selected molecules within these projects. In the process of implementing scientific ideas, the synergy of knowledge and experience of European and American industry scientific experts in the field of synthesis of biologically active compounds, the development and study of dosage forms, as well as the study of nanostructures will be used. We can proudly say that the participation of Farmak pharmaceutical company in such projects is an unprecedented fact in the history of the development of national pharmaceutical science and practice, which opens up new scientific horizons and is a platform for the exchange of ideas and professional experience”, said Oleh Siarkevych, a Member of the Supervisory Board of Farmak JSC.
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...